GCM
NUVB icon

Gladius Capital Management’s Nuvation Bio NUVB Stock Holding History

Gladius Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-30,967
Closed -$46.8K – 386
2023
Q4 		$46.8K Buy
30,967
+14,885
+93% +$19.2K 0.01% 182
2023
Q3 		$21.6K Buy
16,082
+3,198
+25% +$5.32K ﹤0.01% 337
2023
Q2 		$23.2K Sell
12,884
-1,418
-10% -$2.41K ﹤0.01% 292
2023
Q1 		$23.7K Sell
14,302
-5,177
-27% -$10.5K ﹤0.01% 314
2022
Q4 		$37.4K Buy
19,479
+6,257
+47% +$12.7K ﹤0.01% 240
2022
Q3 		$30K Buy
+13,222
New +$37.8K ﹤0.01% 308

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Gladius Capital Management's NUVB Position: Q1 2024 in Review

Gladius Capital Management sold out of Nuvation Bio (NUVB) in Q1 2024, closing a stake of 30,967 shares — an estimated $46.8K sold.

Gladius Capital Management first reported a position in NUVB in Q3 2022 and held it in 6 quarters. The position peaked at $46.8K in Q4 2023. 124 funds tracked by Wall St. Rank hold NUVB as of Q1 2024.

  • Gladius Capital Management reported no remaining Nuvation Bio position as of Q1 2024 after selling out during the quarter.
  • Gladius Capital Management sold 30,967 Nuvation Bio shares in Q1 2024, an estimated $46.8K.
  • Gladius Capital Management first reported a position in Nuvation Bio in Q3 2022 and held it in 6 quarters.
  • Gladius Capital Management's Nuvation Bio position peaked at $46.8K in Q4 2023.
  • 124 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2024.

Based on Gladius Capital Management's 13F filing for Q1 2024, filed 14 May 2024.